Clinical trial

Atopic Dermatitis Treatment Global Market Report 2022: Increasing Adoption of Biological Therapies Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

Due to such factors, the atopic dermatitis treatment market is growing immensely during the forecast period.

Key Points: 
  • Due to such factors, the atopic dermatitis treatment market is growing immensely during the forecast period.
  • Biological therapies such as anti-interleukin antibodies are widely used for treatment in the atopic dermatitis treatment market.
  • A recent wave of biological products prescribed for treating AD will likely create a lucrative opportunity for growth in the atopic dermatitis treatment market.
  • Despite the plethora of therapies currently available to patients with atopic dermatitis (AD), there is still room for improvement within the treatment space.

FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES $5 MILLION GIFT TO ADVANCE CLINICAL TRIALS IN RARE NEURODEVELOPMENTAL DISORDERS

Retrieved on: 
Friday, December 2, 2022

MIAMI, Dec. 2, 2022 /PRNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a $5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmental disorders, a first-of-its-kind flagship center to be directed by Dr. Elizabeth Berry-Kravis. Named the Rush F.A.S.T. Center for Translational Research, it will be the global headquarters for training individuals in how to run neurogenetic clinical trials and deliver innovative interventional therapies that require novel delivery methods and specialized care.

Key Points: 
  • The Center at Rush University Will Be Directed By Dr. Elizabeth Berry-Kravis
    MIAMI, Dec. 2, 2022 /PRNewswire/ --The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a $5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmental disorders, a first-of-its-kind flagship center to be directed by Dr. Elizabeth Berry-Kravis.
  • Center for Translational Research, it will be the global headquarters for training individuals in how to run neurogenetic clinical trials and deliver innovative interventional therapies that require novel delivery methods and specialized care.
  • Today there are over 25 therapeutic programs in the development pipeline for Angelman syndrome, with a majority robustly funded by FAST," said Dr. Allyson Berent, chief science officer at FAST.
  • When a FAST fellow completes their training, they will be able to bring this expertise to other institutions around the world.

FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES $5 MILLION GIFT TO ADVANCE CLINICAL TRIALS IN RARE NEURODEVELOPMENTAL DISORDERS

Retrieved on: 
Friday, December 2, 2022

MIAMI, Dec. 2, 2022 /PRNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a $5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmental disorders, a first-of-its-kind flagship center to be directed by Dr. Elizabeth Berry-Kravis. Named the Rush F.A.S.T. Center for Translational Research, it will be the global headquarters for training individuals in how to run neurogenetic clinical trials and deliver innovative interventional therapies that require novel delivery methods and specialized care.

Key Points: 
  • The Center at Rush University Will Be Directed By Dr. Elizabeth Berry-Kravis
    MIAMI, Dec. 2, 2022 /PRNewswire/ --The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a $5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmental disorders, a first-of-its-kind flagship center to be directed by Dr. Elizabeth Berry-Kravis.
  • Center for Translational Research, it will be the global headquarters for training individuals in how to run neurogenetic clinical trials and deliver innovative interventional therapies that require novel delivery methods and specialized care.
  • Today there are over 25 therapeutic programs in the development pipeline for Angelman syndrome, with a majority robustly funded by FAST," said Dr. Allyson Berent, chief science officer at FAST.
  • When a FAST fellow completes their training, they will be able to bring this expertise to other institutions around the world.

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)

Retrieved on: 
Friday, December 2, 2022

BURNABY, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2022). In addition, the Company is presenting results from the open label extension (OLE) and sub-analyses of data from the XEN1101 Phase 2b X-TOLE clinical trial.

Key Points: 
  • Mr. Ian Mortimer, Xenons President and Chief Executive Officer stated, We continue to advance our portfolio of neurology-focused programs.
  • We also look forward to meeting with leading epileptologists, including Xenon trial investigators, as well as patient advocacy groups at this important meeting.
  • We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
  • Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions.

Neurocrine Biosciences Presents Demographic and Clinical Characteristics Data of Pediatric Patients with SCN8A-Related Epilepsies at AES 2022

Retrieved on: 
Friday, December 2, 2022

SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A-related epilepsies.

Key Points: 
  • SAN DIEGO, Dec. 2, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,today reported demographic and clinical characteristics data from genetic screening-based studies of children with SCN8A-related epilepsies.
  • Data was collected from more than 17,000 patients through Invitae Corporation's Behind the Seizure Program, of which Neurocrine Biosciences is a sponsor.
  • These data (Poster #2.099: Demographic and Clinical Characteristics of Pediatric Patients with SCN8A-related Epilepsies: Results from a No-Charge Epilepsy Gene Panel) will be shared at the AES 2022 Annual Meeting in Nashville, Tennessee, December 26, 2022.
  • Data analysis demonstrated that 36 (0.2%) of the patients had an SCN8A variant that was classified as pathogenic (P) or likely pathogenic (LP).

Patient Recruitment Services and Patient Retention Services Market by Therapeutic Area, Patient Recruitment Step, Trial Phase and Key Geographies: Industry Analysis and Global Forecasts, 2022-2035

Retrieved on: 
Friday, December 2, 2022

In fact, a number of modern technology-enabled offerings are now available to support various aspects of clinical research and patient recruitment.

Key Points: 
  • In fact, a number of modern technology-enabled offerings are now available to support various aspects of clinical research and patient recruitment.
  • What is the current market landscape of the patient recruitment and retention services market?
  • Presently, more than 155 companies have the required capabilities to offer patient recruitment and retention services across different geographical locations.
  • A detailed assessment on the impact of the COVID-19 pandemic on the patient recruitment and retention services market.

Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET

Retrieved on: 
Friday, December 2, 2022

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Key Points: 
  • This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
  • You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov .
  • Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements.
  • All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease

Retrieved on: 
Friday, December 2, 2022

ANAVEX2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.

Key Points: 
  • ANAVEX2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.
  • ANAVEX2-73 treatment met the primary endpoints and reduced clinical decline on the global cognitive and functional scales over 48 weeks in the analysis of the Intent-to-treat (ITT) population.
  • ANAVEX2-73 demonstrated visible improvement in patients with Alzheimers disease.
  • On average, patients, who improved cognitively with ANAVEX2-73 treatment, improved by ADAS-Cog cognition score of -4.03 points.

Theratechnologies Announces Update from Ongoing TH1902 Study

Retrieved on: 
Thursday, December 1, 2022

Theratechnologies voluntarily made the decision to pause enrollment and revisit the study design after consulting with its investigators.

Key Points: 
  • Theratechnologies voluntarily made the decision to pause enrollment and revisit the study design after consulting with its investigators.
  • The current intent for the protocol amendment is to modify the dosage regimen to optimize the delivery of TH1902, with lower doses at more frequent intervals.
  • Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ TechnologyTM for cancer drug development targeting SORT1 receptors.
  • TH1902 is currently Theratechnologies lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology.

Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date

Retrieved on: 
Thursday, December 1, 2022

Boston, MA U.S.A. (December 1, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced that the Companys adjourned 2022 Annual Stockholders Meeting (2022 ASM) set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting (2023 ASM) will be held, as a virtual meeting, on January 19, 2023.

Key Points: 
  • Boston, MA U.S.A. (December 1, 2022) Allarity Therapeutics, Inc. (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced that the Companys adjourned 2022 Annual Stockholders Meeting (2022 ASM) set for December 2, 2022 has been cancelled and a new meeting date for the Annual Stockholders Meeting (2023 ASM) will be held, as a virtual meeting, on January 19, 2023.
  • The annual meeting was rescheduled to January 19, 2023 in light of the new proposals to be considered at the annual meeting.
  • Stockholders of record as of December 6, 2022, will be entitled to notice of, and to vote at, the 2023 ASM.
  • The Company, however, reserves the right to change the record date prior to the 2023 ASM.